Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | PDE9A | O76083 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25300445 | 0.90 | SCN10A (0.45) | SCN2APDE10ANPY5RSCN10A | |
| SCHEMBL25260306 | 0.87 | PTGES (0.36) | FGFR3 | |
| SCHEMBL25260388 | 0.84 | PDE9A (0.35) | SCN2APOLBPDE9ATRPV1SSTR3 | |
| SCHEMBL25299202 | 0.80 | CSNK1E (0.45) | TRPV1 | |
| SCHEMBL23497833 | 0.77 | PDE10A (0.44) | PDE10AGSK3BKLK1KLK5 | |
| SCHEMBL23508051 | 0.77 | CDK2 (0.44) | PDE10ACDK1KLK1KLK5 | |
| SCHEMBL23508220 | 0.74 | CSNK1E (0.40) | CDK1 | |
| SCHEMBL30013417 | 0.74 | EGLN1 (0.34) | GAACDK1 | |
| SCHEMBL23508152 | 0.74 | EGLN1 (0.34) | GAACDK1 | |
| SCHEMBL30013010 | 0.74 | CSNK1E (0.40) | CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCH (DE) | 2025-02-27 | — | — | US | disclosed |
| EP-4463458-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | Deutsches Krebsforschungszentrum (DE) | 2024-11-20 | — | — | EP | disclosed |
| CN-118541372-A | Bicyclic triazine derivatives for the treatment of cancer | 德国癌症研究中心 | 2024-08-23 | — | — | CN | disclosed |
| WO-2023135057-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066370-A1 | BICYCLIC TRIAZINE DERIVATIVES FOR THE TREATMENT OF CANCER | BRCA1, CCNY, CCND2 | SCN2A 3859/4885POLB 208/4885KDM4E 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.